FOR PATIENTSFOR HCPs
dosing schedule
Dosing Schedule
50 mg subcutaneously
once a month1

For patients with RA, SIMPONI® should be given in combination with methotrexate and for patients with PsA or AS, SIMPONI® may be given with or without methotrexate or other nonbiologic Disease-Modifying Antirheumatic Drugs (DMARDs). For patients with RA, PsA, or AS, corticosteroids, non-biologic DMARDs, and/or NSAIDs may be continued during treatment with SIMPONI®.

Injection Number
number of injections
Per
year
121
Dose Form
Dosage form and
strength
50 mg/0.5 mL single-
dose SmartJect®
autoinjector1

or

50 mg/0.5 mL single-
dose prefilled syringe1
Each 50 mg/0.5 mL single-
dose SmartJect® autoinjector contains a prefilled glass
syringe providing 50 mg of SIMPONI® per 0.5 mL of
solution. Also available in a
50 mg/0.5 mL single-dose
prefilled syringe.1
SIMPONI® is intended for use
under the guidance and supervision of a physician.
Patients may self-inject with SIMPONI® after physician
approval and proper training.
Prior to initiating SIMPONI®
and periodically during
therapy, patients should be
evaluated for active
tuberculosis and tested for
latent infection. Prior to
initiating SIMPONI®, patients should be tested for hepatitis
B viral infection.1

NSAID, nonsteroidal anti-inflammatory drug.

SIMPONI® offers fewer than half the number of injections compared with Humira® (adalimumab) and Enbrel® (etanercept) for the treatment of adults with moderately to severely active RA in combination with methotrexate, active PsA alone or in combination with methotrexate, or active AS1-3
  • SIMPONI® autoinjector + MTX1
  • Humira® pen3
  • Enbrel® autoinjector4
  • Minimum number of injections first year
  • table image 12
  • table image 26
  • table image 52
  • Dosing schedule for adults with RA, PsA, and AS
  • 50 mg once a month

  • 40 mg every other week

    Some patients with RA not receiving MTX may benefit from increasing the frequency to 40 mg every week or 80 mg every other week

  • 50 mg once a week
  • Dosage form and strength
  • 50 mg/0.5 mL single-dose prefilled
    syringe or single-dose SmartJect®
    autoinjector.
  • 40 mg/0.4 mL and 80 mg/0.8 mL
    single-dose Humira® Pen
    40 mg/0.4 mL and 80 mg/0.8 mL
    single-dose prefilled glass
    syringe
  • 50 mg/mL single-dose prefilled SureClick® autoinjector or single-dose prefilled syringe
  • Route of administration
  • Subcutaneous injection
  • Subcutaneous injection
  • Subcutaneous injection
  • Indications
  • SIMPONI® is indicated for the treatment of adults with moderately to severely active RA, in combination with MTX, adults with active PsA, alone or in combination with MTX, or adults with active AS.

  • Humira® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA, and reducing signs and symptoms in adult patients with active AS.

    Humira® can be used alone or in combination with MTX or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs) in RA and PsA.

  • Enbrel® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active RA. Enbrel® can be initiated in combination with MTX or used alone. Enbrel® is also indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with PsA. Enbrel® can be used with or without MTX. Enbrel® is indicated for reducing signs and symptoms in patients with active AS.
This presentation is not intended to compare the safety, efficacy, or indications of these treatments. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information, including recommended dosing and administration.
SIMPONI® is intended for use under the guidance and supervision of a physician. Patients may self-inject SIMPONI® after physician approval and proper training.
Prior to initiating SIMPONI® and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection. Prior to initiating SIMPONI®, patients should be tested for hepatitis B viral infection.
Humira is a registered trademark of AbbVie Inc. Enbrel is a registered trademark of Immunex Corporation.

MTX, methotrexate; TNF, tumor necrosis factor.

References: 1. SIMPONI® (golimumab) [Prescribing Information]. Horsham, PA: Janssen Biotech,Inc. 2. Humira® (adalimumab) [Prescribing Information]. Chicago, IL: AbbVie, Inc. 3. Enbrel® (etanercept) [Prescribing Information]. Thousand Oaks, CA: Immunex Corporation.